SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Joe Frazier Synthetic CCD

PatientJoe Frazier
Date of birth1962-01-12
IdentifiersMRN HR-BX004-SYN; SSN (made up) 000-04-5590
Document date2026-11-01
AuthorClarence Whitfield, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

Establishing primary care for type 2 diabetes and high blood pressure above goal: A1c, kidney function, urine albumin, lipids, the yearly liver check with FIB-4, eyes, feet and brain health in a former professional boxer. Concerns: He wants to keep working at his gym and stay strong; He worries about the cost of new medicines; He wants to know whether the blows he took in the ring will affect his memory. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Metformin 1000 mg oral tablet, one tablet twice daily with meals; taken for yearsOne tablet twice daily with mealsOral route2026-02-16activeS
Lisinopril 20 mg oral tablet, one tablet daily; taken for yearsOne tablet dailyOral route2026-02-16activeS
Atorvastatin 40 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-02-16activeS
Amlodipine 5 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-03-02 to 2026-04-13completedS
Amlodipine 10 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-04-13activeS
Semaglutide pen (0.25 mg or 0.5 mg per dose), 0.25 mg under the skin once weekly for four weeks, then 0.5 mg once weekly0.25 mg weekly for four weeks, then 0.5 mg weeklySubcutaneous route2026-03-02 to 2026-05-18completedS
Semaglutide pen (1 mg per dose), 1 mg under the skin once weekly1 mg once weeklySubcutaneous route2026-05-18activeS

Procedures

ProcedureDatesStatusEvidence
Twelve-lead electrocardiogram2026-02-16 to 2026-02-16completedS
Comprehensive diabetic foot examination with a 10-g monofilament, vibration and pulses2026-02-16 to 2026-02-16completedS
Liver transient elastography with controlled attenuation parameter2026-03-02 to 2026-03-02completedS
Liver ultrasound for hepatocellular carcinoma surveillance, baseline2026-03-02 to 2026-03-02completedS
Upper endoscopy to screen for varices2026-04-06 to 2026-04-06completedS
Dilated eye examination at the eye clinic2026-06-22 to 2026-06-22completedS
Liver ultrasound for hepatocellular carcinoma surveillance, six months2026-09-14 to 2026-09-14completedS
Advance care planning conversation, about 18 minutes2026-07-13 to 2026-07-13completedS

Immunizations

DateVaccineStatusEvidence
2026-02-16Tdap vaccinecompletedS
2026-03-02Pneumococcal conjugate vaccine PCV20completedS
2026-03-02Hepatitis B vaccine (HepB-CpG), dose 1 of 2completedS
2026-03-02Hepatitis A vaccine, adult, dose 1 of 2completedS
2026-04-13Hepatitis B vaccine (HepB-CpG), dose 2 of 2completedS
2026-09-14Hepatitis A vaccine, adult, dose 2 of 2completedS
2026-07-13Recombinant zoster vaccine, dose 1 of 2completedS
2026-09-14Recombinant zoster vaccine, dose 2 of 2completedS
2026-09-14Influenza vaccine, inactivated, this seasoncompletedS
2026-09-14COVID-19 vaccine, mRNA, this seasoncompletedS
2026-09-14RSV vaccine, single dosecompletedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
1964Broken left thumb in the 1964 Olympic finalD (CLM-0003)
1964Cataract in the left eye found at 20, with reduced vision in that eye through his boxing career (20/400 in that eye by 1975)D (CLM-0004)
1965 to 1976, and one bout in 1981Professional heavyweight boxing career with many blows to the head, including a 1975 bout stopped when he could no longer seeD (CLM-0005, CLM-0006)
early 2000sDiabetes and high blood pressure, reported publiclyD (CLM-0008)

Family History

No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.

Health Concerns

ConcernStatusEvidence
He wants to keep working at his gym and stay strongactiveS
He worries about the cost of new medicinesactiveS
He wants to know whether the blows he took in the ring will affect his memoryactiveS

Assessment

Most recent measures: Hemoglobin A1c/Hemoglobin.total in Blood 6.8 on 2026-09-14; Glucose [Mass/volume] in Serum or Plasma 168 on 2026-02-16; Sodium [Moles/volume] in Serum or Plasma 140 on 2026-09-14; Potassium [Moles/volume] in Serum or Plasma 4.5 on 2026-09-14; Creatinine [Mass/volume] in Serum or Plasma 1.06 on 2026-09-14; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 78 on 2026-09-14; Albumin/Creatinine [Mass Ratio] in Urine 14 on 2026-09-14; Cholesterol [Mass/volume] in Serum or Plasma 148 on 2026-04-13; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 68 on 2026-04-13; Cholesterol in HDL [Mass/volume] in Serum or Plasma 40 on 2026-04-13; Triglyceride [Mass/volume] in Serum or Plasma 168 on 2026-04-13; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 38 on 2026-09-14; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 31 on 2026-09-14; Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 96 on 2026-02-16; Albumin [Mass/volume] in Serum or Plasma 4.1 on 2026-09-14; Bilirubin.total [Mass/volume] in Serum or Plasma 0.8 on 2026-09-14; Hemoglobin [Mass/volume] in Blood 14.2 on 2026-02-16; Platelets [#/volume] in Blood by Automated count 140 on 2026-09-14; Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma 340 on 2026-02-16; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 4 on 2026-02-16; Total score [AUDIT-C] 2 on 2026-02-16; Liver stiffness by US.transient elastography 17.6 on 2026-03-02; INR in Platelet poor plasma by Coagulation assay 1.1 on 2026-03-02; Alpha-1-Fetoprotein [Mass/volume] in Serum or Plasma 4 on 2026-09-14; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 on 2026-07-13; Total score [MoCA] 26 on 2026-07-13 [S]

Strengths and supports: engagement in care [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Type 2 diabetes with hyperglycemia, about twelve years' duration, A1c 8.4% on metformin; synthetic modern episode linked to his publicly reported diabetesactiveconfirmed E11.65S — Synthetic modern diagnosis; diabetes was reported publicly during his life, but its duration and treatment here are synthetic.
Hypertension above goal on lisinopril (152/92 mmHg in the clinic); synthetic modern episode linked to his publicly reported high blood pressureactiveconfirmed I10S — Synthetic modern diagnosis; high blood pressure was reported publicly during his life.
Raised AST (48 U/L) with mildly low platelets (138) and a FIB-4 score of 3.43 at the yearly liver check, to be evaluatedresolvedconfirmed R74.01S — Synthetic presenting finding, superseded at the two-week visit by the elastography and ultrasound diagnosis.
Metabolic dysfunction-associated steatotic liver disease (MASLD): steatosis on elastography (controlled attenuation parameter 318 dB/m) and ultrasound, with diabetes, obesity, low HDL and high triglycerides, and little alcoholactiveconfirmed K76.0S — Synthetic modern diagnosis. Not part of the public record of his life; chosen to teach surveillance.
Compensated cirrhosis (compensated advanced chronic liver disease) from MASLD: liver stiffness 17.6 kPa, platelets 138, nodular liver surface and a spleen of 13.4 cm on ultrasound; no ascites, encephalopathy, bleeding or jaundice; Child-Pugh Aactiveconfirmed K74.69S — Synthetic modern diagnosis. Not part of the public record of his life; the liver cancer diagnosed three years later in the true frame does not appear in the modern episode.
Hyperlipidemia: LDL 132 mg/dL, HDL 38 and triglycerides 210, not on a statinactiveconfirmed E78.5S — Synthetic laboratory finding.
Obesity, class 1 (BMI 31.4)activeconfirmed E66.811S — Synthetic finding; described without stigma.
Reduced vision in the left eye since a cataract found at 20 (counting fingers at 1 meter); right eye 20/30activeconfirmed H54.62S — Synthetic modern measurement anchored to the documented cataract in his left eye.

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-02-16Hemoglobin A1c/Hemoglobin.total in Blood8.4%Below 5.7% is normal; goal below 7% for himHighS
2026-02-16Glucose [Mass/volume] in Serum or Plasma168mg/dL70-99 mg/dLHighS
2026-02-16Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-02-16Potassium [Moles/volume] in Serum or Plasma4.6mmol/L3.5-5.1 mmol/LNormalS
2026-02-16Creatinine [Mass/volume] in Serum or Plasma1.08mg/dL0.74-1.35 mg/dLNormalS
2026-02-16Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M77mL/min/{1.73_m2}60 or higher without kidney damage markers is not CKDNormalS
2026-02-16Albumin/Creatinine [Mass Ratio] in Urine18mg/gBelow 30 mg/g is normal (A1)NormalS
2026-02-16Cholesterol [Mass/volume] in Serum or Plasma212mg/dL<=199 mg/dLHighS
2026-02-16Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation132mg/dLGoal below 70 mg/dL with diabetes and other risk factorsHighS
2026-02-16Cholesterol in HDL [Mass/volume] in Serum or Plasma38mg/dL>=40 mg/dLLowS
2026-02-16Triglyceride [Mass/volume] in Serum or Plasma210mg/dL<=149 mg/dLHighS
2026-02-16Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma48U/L10-40 U/LHighS
2026-02-16Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma42U/L7-55 U/LNormalS
2026-02-16Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma96U/L40-129 U/LNormalS
2026-02-16Albumin [Mass/volume] in Serum or Plasma4g/dL3.5-5 g/dLNormalS
2026-02-16Bilirubin.total [Mass/volume] in Serum or Plasma0.9mg/dL0.1-1.2 mg/dLNormalS
2026-02-16Hemoglobin [Mass/volume] in Blood14.2g/dL13.5-17.5 g/dLNormalS
2026-02-16Platelets [#/volume] in Blood by Automated count13810*3/uL150-400 10*3/uLLowS
2026-02-16Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma340pg/mL232-1245 pg/mLNormalS
2026-02-16Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S
2026-02-16Total score [AUDIT-C]2{score}S
2026-03-02Liver stiffness by US.transient elastography17.6kPaBelow 8 kPa makes advanced fibrosis unlikely; 15 kPa or higher is consistent with compensated advanced chronic liver diseaseHighS
2026-03-02INR in Platelet poor plasma by Coagulation assay1.1{INR}0.8-1.2NormalS
2026-03-02Alpha-1-Fetoprotein [Mass/volume] in Serum or Plasma4.2ng/mL<=8.3 ng/mLNormalS
2026-04-13Potassium [Moles/volume] in Serum or Plasma4.7mmol/L3.5-5.1 mmol/LNormalS
2026-04-13Creatinine [Mass/volume] in Serum or Plasma1.1mg/dL0.74-1.35 mg/dLNormalS
2026-04-13Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M75mL/min/{1.73_m2}60 or higher without kidney damage markers is not CKDNormalS
2026-04-13Cholesterol [Mass/volume] in Serum or Plasma148mg/dL<=199 mg/dLNormalS
2026-04-13Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation68mg/dLGoal below 70 mg/dL with diabetes and other risk factorsNormalS
2026-04-13Cholesterol in HDL [Mass/volume] in Serum or Plasma40mg/dL>=40 mg/dLNormalS
2026-04-13Triglyceride [Mass/volume] in Serum or Plasma168mg/dL<=149 mg/dLHighS
2026-04-13Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma44U/L10-40 U/LHighS
2026-04-13Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma40U/L7-55 U/LNormalS
2026-05-18Hemoglobin A1c/Hemoglobin.total in Blood7.3%Below 5.7% is normal; goal below 7% for himHighS
2026-07-13Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S
2026-07-13Total score [MoCA]26{score}S
2026-09-14Hemoglobin A1c/Hemoglobin.total in Blood6.8%Below 5.7% is normal; goal below 7% for himHighS
2026-09-14Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
2026-09-14Potassium [Moles/volume] in Serum or Plasma4.5mmol/L3.5-5.1 mmol/LNormalS
2026-09-14Creatinine [Mass/volume] in Serum or Plasma1.06mg/dL0.74-1.35 mg/dLNormalS
2026-09-14Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M78mL/min/{1.73_m2}60 or higher without kidney damage markers is not CKDNormalS
2026-09-14Albumin/Creatinine [Mass Ratio] in Urine14mg/gBelow 30 mg/g is normal (A1)NormalS
2026-09-14Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma38U/L10-40 U/LNormalS
2026-09-14Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma31U/L7-55 U/LNormalS
2026-09-14Albumin [Mass/volume] in Serum or Plasma4.1g/dL3.5-5 g/dLNormalS
2026-09-14Bilirubin.total [Mass/volume] in Serum or Plasma0.8mg/dL0.1-1.2 mg/dLNormalS
2026-09-14Platelets [#/volume] in Blood by Automated count14010*3/uL150-400 10*3/uLLowS
2026-09-14Alpha-1-Fetoprotein [Mass/volume] in Serum or Plasma4ng/mL<=8.3 ng/mLNormalS

Social History

Vital Signs

DateMeasureValueUnitProvenance
2026-02-16Body height182cmS
2026-02-16Body weight104kgS
2026-02-16Body mass index (BMI) [Ratio]31.4kg/m2S
2026-02-16Systolic blood pressure152mm[Hg]S
2026-02-16Diastolic blood pressure92mm[Hg]S
2026-02-16Heart rate76/minS
2026-02-16Respiratory rate16/minS
2026-02-16Body temperature36.7CelS
2026-02-16Oxygen saturation in Arterial blood by Pulse oximetry97%S
2026-03-02Body height182cmS
2026-03-02Body weight103.6kgS
2026-03-02Body mass index (BMI) [Ratio]31.3kg/m2S
2026-03-02Systolic blood pressure148mm[Hg]S
2026-03-02Diastolic blood pressure90mm[Hg]S
2026-03-02Heart rate74/minS
2026-03-02Respiratory rate16/minS
2026-03-02Body temperature36.6CelS
2026-03-02Oxygen saturation in Arterial blood by Pulse oximetry97%S
2026-04-13Body height182cmS
2026-04-13Body weight101.8kgS
2026-04-13Body mass index (BMI) [Ratio]30.7kg/m2S
2026-04-13Systolic blood pressure134mm[Hg]S
2026-04-13Diastolic blood pressure82mm[Hg]S
2026-04-13Heart rate72/minS
2026-04-13Respiratory rate16/minS
2026-04-13Body temperature36.7CelS
2026-04-13Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-05-18Body height182cmS
2026-05-18Body weight99.9kgS
2026-05-18Body mass index (BMI) [Ratio]30.2kg/m2S
2026-05-18Systolic blood pressure126mm[Hg]S
2026-05-18Diastolic blood pressure78mm[Hg]S
2026-05-18Heart rate74/minS
2026-05-18Respiratory rate16/minS
2026-05-18Body temperature36.6CelS
2026-05-18Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-09-14Body height182cmS
2026-09-14Body weight97.2kgS
2026-09-14Body mass index (BMI) [Ratio]29.3kg/m2S
2026-09-14Systolic blood pressure122mm[Hg]S
2026-09-14Diastolic blood pressure76mm[Hg]S
2026-09-14Heart rate72/minS
2026-09-14Respiratory rate16/minS
2026-09-14Body temperature36.7CelS
2026-09-14Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-07-13Body height182cmS
2026-07-13Body weight98.6kgS
2026-07-13Body mass index (BMI) [Ratio]29.8kg/m2S
2026-07-13Systolic blood pressure124mm[Hg]S
2026-07-13Diastolic blood pressure76mm[Hg]S
2026-07-13Heart rate72/minS
2026-07-13Respiratory rate16/minS
2026-07-13Body temperature36.6CelS
2026-07-13Oxygen saturation in Arterial blood by Pulse oximetry98%S

Encounters

DatePurposeStatusProvenance
2026-02-16Establishing primary care for type 2 diabetes and high blood pressure above goal: A1c, kidney function, urine albumin, lipids, the yearly liver check with FIB-4, eyes, feet and brain health in a former professional boxerfinishedS
2026-03-02Two-week review of home blood pressure readings, with liver elastography, a liver ultrasound and the hepatology consultationfinishedS
2026-04-13Eight-week review: blood pressure, lipids, kidney function, semaglutide, the endoscopy result and vaccinesfinishedS
2026-05-18Three-month review: A1c, blood pressure, weight, semaglutide dose and the eye examinationfinishedS
2026-09-14Seven-month review: six-month liver cancer surveillance ultrasound and AFP, A1c, kidney function, urine albumin and vaccinesfinishedS
2026-07-13Periodic adult preventive visitfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Diabetes: continue metformin, an A1c every three months until at goal and then every six months, diabetes self-management education, a vitamin B12 check on long-term metformin, and no medicine that causes low blood sugarcompletedGL-ADA-PHARM-2026, GL-CMID-2026S
Hepatology consultation for a high FIB-4 with mildly low platelets, with transient elastography and a liver ultrasound the same daycompletedGL-AASLD-MASLD-2023, GL-ADA-COMORB-2026S
Liver assessment: FIB-4 from the yearly liver tests, then transient elastography if FIB-4 is 1.3 or higher; hepatitis B, hepatitis C and HIV tests, iron studies, and an alcohol historycompletedGL-AASLD-MASLD-2023, GL-ADA-COMORB-2026, GL-CMID-2026S
Compensated cirrhosis: liver ultrasound with AFP every six months for hepatocellular carcinoma surveillance, upper endoscopy to screen for varices, hepatitis A and B and pneumococcal vaccines, no alcohol, no NSAIDs, acetaminophen no more than 2 g a day, and teaching on the warning signs of decompensationcompletedGL-AASLD-HCC-2023, GL-BAVENO-VII, GL-AASLD-MASLD-2023, GL-CDC-IMZ-2026S
Semaglutide once weekly, increased every four to eight weeks as tolerated, for its cardiovascular and kidney benefit, weight and steatotic liver disease; prior authorization and the manufacturer's assistance program handled by the cliniccompletedGL-ADA-PHARM-2026, GL-ADA-COMORB-2026, GL-AASLD-MASLD-2023S
Blood pressure: a validated home monitor with a large cuff, readings twice a day for a week, a goal below 130/80 mmHg, and less saltcompletedGL-AHA-HTN-2025, GL-CMID-2026S
Amlodipine added to lisinopril and increased to reach the goal, with ankle-swelling checkscompletedGL-AHA-HTN-2025, GL-ADA-CVD-2026S
Cardiovascular risk: atorvastatin 40 mg with a lipid panel at four to twelve weeks; a baseline ECG; aspirin for primary prevention not used because of bleeding riskcompletedGL-ADA-CVD-2026, GL-CMID-2026S
Kidneys: eGFR by the race-free CKD-EPI 2021 equation and urine albumin-to-creatinine ratio at least yearly, and potassium and creatinine on lisinoprilcompletedGL-ADA-CKD-2026, GL-CMID-2026S
Eyes and feet: a dilated eye examination at the eye clinic, a comprehensive foot examination yearly, daily foot checks and callus carecompletedGL-ADA-RETFOOT-2026S
Brain health: a documented cognitive screen at the preventive visit, blood pressure and glucose control, sleep, hearing and mood checks, and an honest conversation that chronic traumatic encephalopathy cannot be diagnosed during lifecompletedGL-NINDS-TES-2021, GL-CMID-2026S
Cost and access: low-cost generics, 90-day supplies, and help with coverage for any brand-name medicinecompletedGL-ADA-POP-2026S

Goals

GoalTargetStatusOutcomeProvenance
A1c below 7% within six to nine months, without low blood sugar2026-09-14completed8.4% to 6.8% at seven months; no low blood sugarS
Blood pressure below 130/80 mmHg in the clinic and at home2026-09-14completed122/76 in the clinic; home average 124/78S
LDL cholesterol below 70 mg/dL2026-04-13completed132 to 68 mg/dL on atorvastatinS
Weight loss of 7 to 10% for liver health within a year2026-09-14active104.0 to 97.2 kg (6.5%) at seven monthsS
Liver cancer surveillance by ultrasound with AFP every six months, on time2026-09-14completedBaseline and six-month ultrasounds with AFP on schedule; no focal lesion; AFP 4.2 and 4.0 ng/mLS
No alcohol, to protect the liver2026-09-14completedNo alcohol since the two-week visitS

Functional Status

Mental Status